Loading
Rite AID Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Dec 2021.
Rite AID Corp: what insiders have been doing
This page follows insider dealings at Rite AID Corp as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Philadelphia, United States. The group dates from 1962. No insider at Rite AID Corp has published a filing in the past twelve months. The most recent one dates from 28 July 2023.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
77
Thresholds
n/a
Buy Volume
€177,151
1 ops. · all time
Sell Volume
€545,868
6 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2019FY ended March 2019 · cache
Income statement
RevenueUS$18.6B
Gross profitUS$4.1B22% margin
Net income-US$619.2M-3.3% margin
Last declaration on 28 July 2023
Declarations77 total
4,968 shares@ US$1.585.0% of flowCommon StockSEC:0001209191-23-043665:0
6,934 shares@ US$1.5810.1% of flowCommon StockSEC:0001209191-23-043662:0
17,349 shares@ US$1.5811.4% of flowCommon StockSEC:0001209191-23-043667:0
8,226 shares@ US$1.645.6% of flowCommon StockSEC:0001209191-23-042013:0
3,029 shares@ US$1.644.6% of flowCommon StockSEC:0001209191-23-042010:0
2,292 shares@ US$1.642.4% of flowCommon StockSEC:0001209191-23-042012:0
208 shares@ US$1.6458.6% of flowCommon StockSEC:0001209191-23-042005:0
147 shares@ US$1.6441.4% of flowCommon StockSEC:0001209191-23-042005:1
5,953 shares0Common StockSEC:0001209191-23-031415:0
11,416 shares0Common StockSEC:0001209191-23-025667:0
5,547 shares0Common StockSEC:0001209191-23-025666:0
2,076 shares@ US$3.7611.1% of flowCommon StockSEC:0001209191-23-007647:0
2,728 shares@ US$10.5124.5% of flowCommon StockSEC:0001209191-22-046633:0
37,370 shares@ US$11.0520.8% of flowCommon StockSEC:0001209191-22-045828:0
21,505 shares0Common StockSEC:0001209191-22-043528:0
49,509 shares0Common StockSEC:0001209191-22-043523:0
21,505 shares0Common StockSEC:0001209191-22-043562:0
21,505 shares0Common StockSEC:0001209191-22-043526:0
57,686 shares0Common StockSEC:0001209191-22-043527:0
21,505 shares0Common StockSEC:0001209191-22-043517:0
56,236 shares0Common StockSEC:0001209191-22-043516:0
18,429 shares0Common StockSEC:0001209191-22-043518:0
429,858 shares0Common StockSEC:0001209191-22-043515:0
47,177 shares0Common StockSEC:0001209191-22-043519:0
21,505 shares0Common StockSEC:0001209191-22-043514:0
25 of 77 declarations
About Rite AID Corp
Rite AID Corp (ticker RAD) is a long-standing U.S. pharmacy retailer listed on the NYSE/NASDAQ and incorporated in the United States. The company traces its roots back to 1962, when it opened its first store in Scranton, Pennsylvania under the Thrif D Discount Center name; it later adopted the Rite Aid Corporation name in 1968. Over time, Rite Aid built a recognizable neighborhood drugstore model centered on prescription fulfillment, convenience retail, and consumer health products.
For decades, the company grew into one of the better-known pharmacy chains in the United States, expanding across both the East Coast and West Coast through organic growth and acquisitions. Its business model historically combined retail pharmacy with front-end merchandise, including over-the-counter medicines, wellness and beauty products, personal care items, seasonal goods, and other everyday convenience categories. Rite Aid also previously operated adjacent pharmacy-services businesses, including a PBM platform through Elixir, which it later sold. The company has used private-label and proprietary consumer brands as part of its merchandising strategy, reinforcing repeat visits and margin support in lower-ticket health-and-wellness categories.
Read moreShow less
Geographically, Rite Aid historically operated a large national store network with a strong community-based footprint. The company relocated its headquarters from Camp Hill to Philadelphia’s Navy Yard district, reflecting a strategic effort to modernize its operating platform and corporate presence. Its competitive positioning has long been shaped by intense rivalry from CVS, Walgreens, supermarkets, and mass merchants, all of which exert pressure on prescription economics, front-end traffic, and store-level productivity.
Recent developments are overwhelmingly defined by financial distress and restructuring. In May 2025, Rite Aid filed for a second Chapter 11 bankruptcy after its earlier turnaround failed to stabilize the business. Subsequent reporting indicated widespread store closures and the sale of pharmacy assets to competitors in a court-supervised process. As a result, the investment case has shifted from traditional retail-pharmacy growth analysis to a restructuring and liquidation framework, where asset sales, creditor recoveries, and the orderly transfer of prescription files became the primary drivers of value.
For investors, Rite Aid is best viewed as a distressed U.S. healthcare-retail situation rather than a normal going-concern growth story. Its listing on the NYSE/NASDAQ and its U.S. domicile remain relevant, but the fundamental narrative is now dominated by bankruptcy proceedings, asset disposition, and residual-value uncertainty.
